Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total value of $97,715.48. Following the completion of the sale, the insider now directly owns 110,673 shares in the company, valued at $799,059.06. This trade represents a 10.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06.

Candel Therapeutics Trading Down 13.4 %

CADL stock opened at $6.66 on Friday. The stock’s 50 day simple moving average is $6.61 and its 200 day simple moving average is $6.28. Candel Therapeutics, Inc. has a 12-month low of $1.16 and a 12-month high of $14.60. The stock has a market capitalization of $216.32 million, a PE ratio of -3.85 and a beta of -1.20.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. HB Wealth Management LLC raised its position in Candel Therapeutics by 54.1% in the 4th quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after buying an additional 30,642 shares during the last quarter. Barclays PLC raised its holdings in shares of Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after purchasing an additional 21,971 shares during the last quarter. Geode Capital Management LLC lifted its position in Candel Therapeutics by 12.8% during the third quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after purchasing an additional 51,111 shares during the period. State Street Corp boosted its holdings in Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after purchasing an additional 19,207 shares during the last quarter. Finally, Atom Investors LP bought a new stake in Candel Therapeutics in the 3rd quarter worth approximately $103,000. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.